• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

    Author(s)
    Nash, P
    Coates, LC
    Kivitz, AJ
    Mease, PJ
    Gladman, DD
    Covarrubias-Cobos, JA
    Fleishaker, D
    Wang, C
    Kudlacz, E
    Menon, S
    Fallon, L
    Hendrikx, T
    Kanik, KS
    Griffith University Author(s)
    Nash, Peter
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Aim Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report tofacitinib safety, tolerability and efficacy in active PsA patients from an open‐label extension (LTE) study (OPAL Balance; NCT01976364; November 2017 data‐cut; database not locked). Method Eligible patients from 2 Phase (P)3 tofacitinib PsA studies (OPAL Broaden; OPAL Beyond) entered a 3‐year LTE. Patients received tofacitinib 5 mg BID to Month (M)1, after which dose adjustments between 5 and 10 mg BID were permitted to improve efficacy, or for safety reasons. Patients receiving a csDMARD at P3 study entry ...
    View more >
    Aim Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report tofacitinib safety, tolerability and efficacy in active PsA patients from an open‐label extension (LTE) study (OPAL Balance; NCT01976364; November 2017 data‐cut; database not locked). Method Eligible patients from 2 Phase (P)3 tofacitinib PsA studies (OPAL Broaden; OPAL Beyond) entered a 3‐year LTE. Patients received tofacitinib 5 mg BID to Month (M)1, after which dose adjustments between 5 and 10 mg BID were permitted to improve efficacy, or for safety reasons. Patients receiving a csDMARD at P3 study entry continued the same csDMARD in the LTE. Primary endpoints: incidence and severity of adverse events (AEs) through M36; change from baseline (Δ) in laboratory values. Efficacy was evaluated through M30 (when N>50). Result 686 patients were treated in OPAL Balance; 468 (68.2%) remained in the study at data cut‐off. Mean (range) LTE tofacitinib exposure was 614 (1–1032) days. To M36, 2189 AEs were reported in 546 patients (79.6%); 95 (13.8%) had serious AEs; 59 (8.6%) discontinued due to AEs. Serious infections occurred in 12 patients (1.7%), herpes zoster in 20 (2.9%), major adverse cardiovascular events in 5 (0.7%), malignancies in 24 (3.5%; including 12 NMSC) and uveitis in 2 (0.3%). No gastrointestinal perforations or inflammatory bowel disease were reported. There were 5 deaths, all unrelated to study drug (investigator‐determined). ALT ≥3x ULN occurred in 27 patients (4.0%); AST ≥3x ULN in 15 (2.2%). Eight patients (1.2%) discontinued (protocol‐mandated) due to laboratory changes. ACR responses, ΔHAQ‐DI, PASI75 response, ΔLEI, ΔDSS and ΔPain were maintained through M30. Conclusions Over 36 months in the LTE, the safety profile of tofacitinib in active PsA patients was generally similar to that of P3 studies. No new safety risks were identified. Efficacy was maintained over time across various PsA disease domains.
    View less >
    Conference Title
    Internal Medicine Journal
    Volume
    48
    Issue
    S4
    Publisher URI
    https://onlinelibrary.wiley.com/doi/10.1111/imj.13801
    Subject
    Cardiorespiratory Medicine and Haematology
    Clinical Sciences
    Public Health and Health Services
    Science & Technology
    Life Sciences & Biomedicine
    Medicine, General & Internal
    General & Internal Medicine
    Publication URI
    http://hdl.handle.net/10072/402503
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander